BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 32539316)

  • 21. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
    Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
    Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.
    Veeraputhiran M; Yang L; Sundaram V; Arai S; Lowsky R; Miklos D; Meyer E; Muffly L; Negrin R; Rezvani A; Shizuru J; Weng WK; Johnston L
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1744-1748. PubMed ID: 28668491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).
    Saraceni F; Labopin M; Forcade E; Kröger N; Socié G; Niittyvuopio R; Cornelissen JJ; Labussière-Wallet H; Blaise D; Choi G; Byrne JL; Guillerm G; Marchand T; Esteve J; Bazarbachi A; Savani B; Olivieri A; Nagler A; Mohty M
    Cancer Med; 2021 Jan; 10(1):23-33. PubMed ID: 33242374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
    van Gelder M; Ziagkos D; de Wreede L; van Biezen A; Dreger P; Gramatzki M; Stelljes M; Andersen NS; Schaap N; Vitek A; Beelen D; Lindström V; Finke J; Passweg J; Eder M; Machaczka M; Delgado J; Krüger W; Raida L; Socié G; Jindra P; Afanasyev B; Wagner E; Chalandon Y; Henseler A; Schoenland S; Kröger N; Schetelig J;
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):667-675.e2. PubMed ID: 28694085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic Cell Transplant-Composite Risk (HCT-CR): A Novel Predictor of Prognosis in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Yegin ZA; Özkurt ZN; Dikyar A; Kaynar LA; Karacaoğlu Ö; Yağcı M
    Transplant Proc; 2021; 53(6):2013-2020. PubMed ID: 34246474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of the European Group for Blood and Marrow Transplantation (EBMT) risk score in patients receiving allogeneic hematopoietic stem cell transplantation at a single center in Japan.
    Numata A; Tanaka M; Matsumoto K; Takasaki H; Tachibana T; Fujimaki K; Sakai R; Fujisawa S; Tomita N; Fujita H; Maruta A; Ishigatsubo Y; Kanamori H
    Clin Transplant; 2014 Apr; 28(4):403-9. PubMed ID: 24655161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
    Gilleece MH; Labopin M; Savani BN; Yakoub-Agha I; Socié G; Gedde-Dahl T; Blaise D; Byrne JL; Craddock C; Cornelissen JJ; Arcese W; Forcade E; Crawley C; Polge E; Mohty M; Nagler A
    Leukemia; 2020 Jan; 34(1):87-99. PubMed ID: 31363160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants.
    Majhail NS; Brunstein CG; McAvoy S; DeFor TE; Al-Hazzouri A; Setubal D; Arora M; Le CT; Wagner JE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):985-992. PubMed ID: 18721761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.
    Michelis FV; Messner HA; Atenafu EG; McGillis L; Lambie A; Uhm J; Alam N; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
    Bone Marrow Transplant; 2015 Nov; 50(11):1405-10. PubMed ID: 26168067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.
    Malard F; Labopin M; Cho C; Blaise D; Papadopoulos EB; Passweg J; O'Reilly R; Forcade E; Maloy M; Volin L; Castro-Malaspina H; Hicheri Y; Jakubowski AA; Orvain C; Giralt S; Mohty M; Nagler A; Perales MA
    J Hematol Oncol; 2018 Oct; 11(1):127. PubMed ID: 30342553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
    Ciurea SO; Labopin M; Socie G; Volin L; Passweg J; Chevallier P; Beelen D; Milpied N; Blaise D; Cornelissen JJ; Fegueux N; Polge E; Kongtim P; Rondon G; Esteve J; Mohty M; Savani BN; Champlin RE; Nagler A
    Cancer; 2018 May; 124(10):2134-2141. PubMed ID: 29469961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission.
    Versluis J; Labopin M; Niederwieser D; Socie G; Schlenk RF; Milpied N; Nagler A; Blaise D; Rocha V; Cornelissen JJ; Mohty M
    Leukemia; 2015 Jan; 29(1):51-7. PubMed ID: 24913728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
    Saad A; Mahindra A; Zhang MJ; Zhong X; Costa LJ; Dispenzieri A; Drobyski WR; Freytes CO; Gale RP; Gasparetto CJ; Holmberg LA; Kamble RT; Krishnan AY; Kyle RA; Marks D; Nishihori T; Pasquini MC; Ramanathan M; Lonial S; Savani BN; Saber W; Sharma M; Sorror ML; Wirk BM; Hari PN
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):402-408.e1. PubMed ID: 24342394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD34
    Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
    Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
    Sengsayadeth S; Gatwood KS; Boumendil A; Labopin M; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gilleece MH; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
    Blood Adv; 2018 Aug; 2(16):2127-2135. PubMed ID: 30143527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.
    Sorror ML; Logan BR; Zhu X; Rizzo JD; Cooke KR; McCarthy PL; Ho VT; Horowitz MM; Pasquini MC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1479-87. PubMed ID: 25862591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
    Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.
    Vaughn JE; Storer BE; Armand P; Raimondi R; Gibson C; Rambaldi A; Ciceri F; Oneto R; Bruno B; Martin PJ; Sandmaier BM; Storb R; Sorror ML
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1418-24. PubMed ID: 25862589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.